Novartis Investigative Site

Barcelona, Catalonia 8036

5 studies enrolling now · 256 studies all time

What they study most

3rd Line GIST, ALK-activated Tumors, Acromegaly, Acute Decompensated Heart Failure, Acute Heart Failure, Acute Kidney Injury Following Cardiac Surgery, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), Advanced Endometrial Cancer, Advanced Gastric Cancer

Studies at this site

• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria — Recruiting now
• Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. — Recruiting now
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Recruiting now
• CAR-T Long Term Follow Up (LTFU) Study — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) — Running, not enrolling
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors — Stopped early
• A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. — Stopped early
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
• Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent — Stopped early
• A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — Running, not enrolling
• Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis — Stopped early
• Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis — Completed
• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients — Completed
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — Running, not enrolling
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
• Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam — Completed
• Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension — Stopped early
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments — Completed
• An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. — Completed
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers — Running, not enrolling
• A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer — Stopped early
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. — Stopped early
• Study of Diagnostic Performance of [18F]CTT1057 in BCR — Completed
• Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) — Stopped early
• Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients — Completed
• Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders — Stopped early
• Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS — Stopped early
• Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection — Completed
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies — Stopped early
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma — Stopped early
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed
• A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands — Completed
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors — Stopped early
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS — Completed
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). — Stopped early
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis — Stopped early
• Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF — Completed
• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension — Stopped early
• A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab — Stopped early
• Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy — Stopped early
• Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) — Completed
• A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma — Stopped early